お知らせ • Aug 01
Moleculin Biotech Reports Positive Interim Data from MIRACLE R/R AML Trial with Annamycin
Moleculin Biotech announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial (MB-108) of Annamycin in combination with cytarabine (AnnAraC) for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). With 62 subjects evaluable to date, the preliminary blinded complete remission (CR) rate is 24% and the composite complete remission (CRc) rate is 37%. Of those 62 subjects, 30, or 48%, had previously received a venetoclax-based regimen. Among that subgroup, the preliminary blinded CR and CRc rates were 23% and 37%, respectively, essentially identical to the evaluable population as a whole. Prior venetoclax failure—a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months—shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part A. No evidence of cardiotoxicity continues to differentiate Annamycin from conventional anthracyclines. Because this analysis remains blinded, it includes subjects randomized to the control arm and is therefore expected to be lower than the unblinded Annamycin-arm results reported at the June 2026 interim analysis, in which CRc reached 50% and 57% in the two Annamycin arms versus 29% for control. The two sets of figures are not directly comparable. Across three successive blinded analyses, at 30, 45 and 62 evaluable subjects, the blinded CRc has remained within a narrow band of approximately 37% to 40%, while the proportion of subjects entering the trial after failure of a first-line venetoclax-based regimen has risen from 31.1% in the n=45 population to 48% today. Enrollment stands at 74 of 90 subjects, and additional subjects continue to be identified by site investigators. The Company expects to treat the 90th subject in September 2026, with unblinding of the comprehensive Part A data anticipated in the December 2026 to February 2027 timeframe. The trial continues with no evidence of cardiotoxicity. MIRACLE is a pivotal Phase 2/3 study of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy. Part A of the trial compares two different doses of Annamycin plus cytarabine to a control arm of cytarabine plus placebo, all with just one cycle of therapy. The comprehensive unblinded Part A results expected beginning in the planned December 2026 to February 2027 timeframe have the potential to validate Annamycin’s differentiated profile in a randomized setting, support advancement into Part B, strengthen the regulatory pathway, and meaningfully expand strategic partnering opportunities. Venetoclax-based regimens have become a standard of care for first-line treatment of patients who are older or otherwise unfit for intensive chemotherapy, and outcomes reported after failure of those regimens are poor. In a retrospective analysis of 41 patients with relapsed or refractory AML following failure of frontline venetoclax plus a hypomethylating agent, 3 of the 24 patients who went on to receive salvage therapy, or 13%, achieved complete remission or complete remission with incomplete hematologic recovery, the same response categories that comprise CRc under the MIRACLE protocol, which does not include morphologic leukemia-free state, and median overall survival from the onset of relapsed or refractory disease was 2.4 months (Maiti et al., Haematologica 2021;106(3):894-898). That analysis was retrospective, drawn from a single institution and used heterogeneous salvage regimens, and it is not a controlled comparison to the MIRACLE trial. The preliminary blinded CRc rate reported above for the venetoclax-failure subgroup is descriptive only, is based on 30 subjects, includes subjects randomized to the control arm, and that the trial is not powered for subgroup comparisons. The interim analysis, announced at the end of June, demonstrated a clear efficacy advantage for both Annamycin treatment arms, 190 mg/m² plus HiDAC (n=14) and 230 mg/m² plus HiDAC (n=14), over the HiDAC control arm (n=17). CR reached 43% and 36% in the respective Annamycin cohorts, compared with 12% for control, while CRc reached 50% and 57%, respectively, versus 29% for the control arm. The n=45 population contained 75.6% over 60 years of age, 55.6% 7+3 and 31.1% venetoclax regimens for first line (1L) therapies. The remission rates for all three arms, including the control arm, reflect outcomes measured after only a single cycle of therapy, as specified by the MIRACLE protocol. The most commonly cited historical benchmarks in this setting, including the MIRROS and CLASSIC I studies, as well as Moleculin’s own MB-106 study, permitted multiple cycles of treatment. The Company therefore expected absolute remission rates for both the control and Annamycin arms in this single-cycle interim analysis to be lower than those reported in such multi-cycle datasets, and believes the most meaningful comparison (and the one which will be the primary factor in determining new drug approval) is the performance of the final optimum-dose Annamycin arm relative to the concurrent, randomized control arm evaluated on the same single-cycle basis. The MIRACLE study (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) is a Phase 2/3, global multi-center, randomized, double-blind, placebo-controlled, adaptive-design clinical trial whereby data from the Phase 2 (Part A) portion will be combined with the Phase 3 (Part B) portion for purposes of measuring its primary efficacy endpoint. Part A of the MIRACLE trial is designed to evaluate the effectiveness of Annamycin in two dosing arms (190 mg/m² and 230 mg/m²) in combination with cytarabine (also referred to as Ara-C) as compared to a control arm of cytarabine plus placebo. The protocol for the MIRACLE trial allows for the limited unblinding of preliminary primary efficacy data (Complete Remission, or “CR”) of the three arms at 45 subjects in Part A, in addition to an expanded data set including primary, secondary and exploratory endpoints at the conclusion of Part A (at 90 total subjects).